WO2008014386A3 - Traitement de tumeurs chez des patients pédiatriques avec des antagonistes des récepteurs du facteur de croissance épidermique - Google Patents

Traitement de tumeurs chez des patients pédiatriques avec des antagonistes des récepteurs du facteur de croissance épidermique Download PDF

Info

Publication number
WO2008014386A3
WO2008014386A3 PCT/US2007/074448 US2007074448W WO2008014386A3 WO 2008014386 A3 WO2008014386 A3 WO 2008014386A3 US 2007074448 W US2007074448 W US 2007074448W WO 2008014386 A3 WO2008014386 A3 WO 2008014386A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumors
treatment
growth factor
receptor antagonists
factor receptor
Prior art date
Application number
PCT/US2007/074448
Other languages
English (en)
Other versions
WO2008014386A2 (fr
Inventor
Eric Rowinsky
Original Assignee
Imclone Systems Inc
Eric Rowinsky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc, Eric Rowinsky filed Critical Imclone Systems Inc
Priority to MX2008016187A priority Critical patent/MX2008016187A/es
Priority to CA002654911A priority patent/CA2654911A1/fr
Priority to EA200870603A priority patent/EA200870603A1/ru
Priority to EP07813400A priority patent/EP2043688A4/fr
Priority to BRPI0712368-0A priority patent/BRPI0712368A2/pt
Priority to JP2009522001A priority patent/JP2009544736A/ja
Priority to AU2007279261A priority patent/AU2007279261A1/en
Publication of WO2008014386A2 publication Critical patent/WO2008014386A2/fr
Publication of WO2008014386A3 publication Critical patent/WO2008014386A3/fr
Priority to TNP2008000512A priority patent/TNSN08512A1/en
Priority to NO20085182A priority patent/NO20085182L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés de thérapie de combinaison pour traiter des tumeurs pédiatriques par l'administration d'un antagoniste de EGFR et d'un agent chimiothérapeutique. L'invention concerne également des procédés qui comprennent le traitement de tumeurs pédiatriques réfractaires.
PCT/US2007/074448 2006-07-27 2007-07-26 Traitement de tumeurs chez des patients pédiatriques avec des antagonistes des récepteurs du facteur de croissance épidermique WO2008014386A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2008016187A MX2008016187A (es) 2006-07-27 2007-07-26 Tratamiento de tumores en pacientes pediatricos con antagonistas del receptor del factor de crecimiento epidermico.
CA002654911A CA2654911A1 (fr) 2006-07-27 2007-07-26 Traitement de tumeurs chez des patients pediatriques avec des antagonistes des recepteurs du facteur de croissance epidermique
EA200870603A EA200870603A1 (ru) 2006-07-27 2007-07-26 Лечение опухолей у педиатрических пациентов антагонистами рецептора эпидермального фактора роста
EP07813400A EP2043688A4 (fr) 2006-07-27 2007-07-26 Traitement de tumeurs chez des patients pédiatriques avec des antagonistes des récepteurs du facteur de croissance épidermique
BRPI0712368-0A BRPI0712368A2 (pt) 2006-07-27 2007-07-26 método para inibir o crescimento de um tumor em um paciente pediátrico
JP2009522001A JP2009544736A (ja) 2006-07-27 2007-07-26 小児患者における腫瘍の上皮増殖因子受容体アンタゴニストによる治療
AU2007279261A AU2007279261A1 (en) 2006-07-27 2007-07-26 Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists
TNP2008000512A TNSN08512A1 (en) 2006-07-27 2008-12-11 Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists
NO20085182A NO20085182L (no) 2006-07-27 2008-12-11 Behandling av tumorer hos pediatrikse pasienter med antagonister mot epidermal vekstfaktorresptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83348706P 2006-07-27 2006-07-27
US60/833,487 2006-07-27

Publications (2)

Publication Number Publication Date
WO2008014386A2 WO2008014386A2 (fr) 2008-01-31
WO2008014386A3 true WO2008014386A3 (fr) 2008-07-03

Family

ID=38982334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/074448 WO2008014386A2 (fr) 2006-07-27 2007-07-26 Traitement de tumeurs chez des patients pédiatriques avec des antagonistes des récepteurs du facteur de croissance épidermique

Country Status (15)

Country Link
EP (1) EP2043688A4 (fr)
JP (1) JP2009544736A (fr)
KR (1) KR20090033841A (fr)
CN (1) CN101484186A (fr)
AU (1) AU2007279261A1 (fr)
BR (1) BRPI0712368A2 (fr)
CA (1) CA2654911A1 (fr)
CR (1) CR10486A (fr)
EA (1) EA200870603A1 (fr)
EC (1) ECSP089011A (fr)
MX (1) MX2008016187A (fr)
NO (1) NO20085182L (fr)
TN (1) TNSN08512A1 (fr)
WO (1) WO2008014386A2 (fr)
ZA (1) ZA200810600B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021019167A2 (pt) * 2019-03-27 2021-12-21 Nat Res Council Canada Anticorpos anti-egfrviii e fragmentos de ligação a antígeno dos mesmos

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
COMBS ET AL.: "Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and termozolomide (GERT)-phase I/II trial: study protocol", BMC CANCER, vol. 6, no. 133, 18 May 2006 (2006-05-18), pages 1 - 9, XP021016124 *
CUNNINGHAM ET A.: "Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer", N. ENG. J. MED., vol. 351, no. 4, 22 July 2004 (2004-07-22), pages 337 - 345, XP008075821 *
DAW ET AL.: "Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study", J. CLIN. ONCOL., vol. 23, no. 25, 1 September 2005 (2005-09-01), pages 6172 - 6180, XP008100098 *
ELLER ET AL.: "Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme", NEUROSURGERY, vol. 51, no. 4, October 2002 (2002-10-01), pages 1005 - 1013, XP008100096 *
ELLER ET AL.: "Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo", NEUROSURGERY, vol. 56, no. 1, 2005, pages 155 - 162, XP008100097 *
HO ET AL.: "Proliferation of human neuroblastoma mediated by the epidermal growth factor receptor", CANCER RES., vol. 65, no. 21, 1 November 2005 (2005-11-01), pages 9868 - 9875, XP008100099 *
See also references of EP2043688A4 *

Also Published As

Publication number Publication date
TNSN08512A1 (en) 2010-04-14
CN101484186A (zh) 2009-07-15
EP2043688A4 (fr) 2009-11-11
WO2008014386A2 (fr) 2008-01-31
EP2043688A2 (fr) 2009-04-08
BRPI0712368A2 (pt) 2012-06-05
KR20090033841A (ko) 2009-04-06
CA2654911A1 (fr) 2008-01-30
EA200870603A1 (ru) 2009-06-30
ZA200810600B (en) 2009-11-25
JP2009544736A (ja) 2009-12-17
MX2008016187A (es) 2009-01-20
AU2007279261A1 (en) 2008-01-31
NO20085182L (no) 2009-04-24
CR10486A (es) 2009-02-23
ECSP089011A (es) 2009-01-30

Similar Documents

Publication Publication Date Title
IL238913A0 (en) Vegf-specific antagonists for adjuvant therapy and treatment of early-stage tumors
EP2046973A4 (fr) Procédés d'identification, d'évaluation, et de traitement de patients soumis à une thérapie anticancéreuse
ZA201003779B (en) Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
IL179515A0 (en) Method of administering and using vegf inhibitors for the treatment of human cancer
ZA200709780B (en) Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues
WO2010068866A3 (fr) Particules thérapeutiques pour administration parentérale, et procédés de fabrication et d'utilisation associés
WO2006110175A3 (fr) Traitement combinant le bortezomib et un inhibiteur des kinases du recepteur du facteur de croissance epidermique
EP1985302A4 (fr) Médicament pour le traitement de tumeurs et son utilisation
EP2211913A4 (fr) Administration systémique d'agents de chlorotoxine pour le diagnostic et le traitement de tumeurs
EP2712930A3 (fr) Marqueurs pharmacodynamiques par induction alpha d'interféron
WO2007050784A3 (fr) Traitement a base de combinaisons de medicaments a rapport fixe pour le traitement de tumeurs solides
MX2009011357A (es) Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos.
WO2006110176A3 (fr) Traitement combinant un rayonnement et un inhibiteur de kinase du recepteur du facteur de croissance epidermique
NZ598145A (en) Folate-targeted diagnostics and treatment
WO2011009020A3 (fr) Composés et compositions pour une utilisation en photothérapie et dans le traitement d'une maladie néovasculaire oculaire et de cancers
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
PL1781296T3 (pl) Pochodne chinazolinowe i ich zastosowanie w leczeniu nadpłytkowości
WO2009137543A3 (fr) Procédés pour le dépistage et le traitement du cancer du sein
IL197157A0 (en) Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase
HK1145316A1 (zh) 用於中樞神經系統疾病或腫瘤的成像、診斷和/或治療的化合物
WO2008060899A3 (fr) Procédés de dépistage et de traitement du cancer du sein
WO2007039123A3 (fr) Traitement combine
WO2007133796A3 (fr) Procédés et compositions de traitement de l'apnée du sommeil
WO2005070460A3 (fr) Polytherapie au moyen d'antagonistes des recepteurs 5-ht1a et 5-ht1b
WO2008025033A3 (fr) traitement de l'anémie aplastique

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780024999.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07813400

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2654911

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: CR2008-010486

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 12008502750

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2007279261

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008121988

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 573608

Country of ref document: NZ

Ref document number: 195938

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 08133771

Country of ref document: CO

Ref document number: MX/A/2008/016187

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007813400

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5258/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009522001

Country of ref document: JP

Ref document number: 1020087031606

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200870603

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2007279261

Country of ref document: AU

Date of ref document: 20070726

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: PI0712368

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081219